Clinicians should be aware that people who have SGLT-2 inhibitors prescribed for diabetes are more likely to develop EDKA than those using SGLT-2 inhibitors for heart failure or chronic kidney disease treatment, as mentioned above. The gene discussed is SLC5A2; the disease is diabetes mellitus.